Affinity Technologies receives Japanese patent for CyPath Lung test to detect lung cancer early: San Antonio Saturday, October 10, 2026, 13:00 Hrs [IST] bioAffinity Technologie ...
InvestorsHub on MSN
BioAffinity Technologies receives Japanese patent allowance for CyPath Lung AI diagnostic test
The Japanese Patent Office has signalled its intention to grant patent protection for bioAffinity Technologies’ noninvasive ...
Lung cancer remains one of the malignancies with the highest incidence and mortality worldwide. Clinical practice has long been plagued by core dilemmas, including insufficient sensitivity in early ...
Lung cancer kills more people worldwide than any other malignancy, and the reason is painfully simple: it is usually caught too late. More than 60 percent of patients receive their diagnosis at an ...
Grade 9 learner Brandon Mashandudze received top honours from Harvard Medical School’s Dr Chi-Fu Jeffrey Yang and the ...
Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.
SAN ANTONIO, October 08, 2026--bioAffinity Technologies receives notice of allowance for new patent in Japan covering its noninvasive CyPath Lung diagnostic test for lung cancer.
Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung Presentation to address current challenges in pulmonary nodule management and to discuss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results